Our Team
Kito Tosetti
Founder & CEO
Kito Tosetti – President & co-founder: Mr. Tosetti has served as the Chief Executive Officer of CTF MEG from 2016 to 2021. During his term at CTF, Mr. Tosetti turned around CTF, positioning the company as a leading MEG producer. Before joining CTF, he was the Chief Executive Officer of iCell Therapeutics, a developer of smart targeted treatments to address the unmet needs of certain types of cancer and cardiovascular diseases such as restenosis, aneurysms, and atherosclerosis. Earlier in his career, Mr. Tosetti co–founded and served as the President & Chief Executive Officer of MIV Therapeutics from its inception to publicly traded on the NASDAQ exchange.
Dr. Sam Doesburg
Founder & CSO
Dr. Sam Doesburg – Chief Neuroscience Officer and co-founder: A neuroscientist focusing in the application of MEG imaging for mapping electrophysiological networks and their alteration in clinical child populations with a focus on ASD. Dr. Doesburg earned a Ph.D. in Neuroscience from the University of British Columbia before completing a postdoctoral fellowship at the BC Children’s Hospital and working as a Scientist at the Hospital for Sick Children from 2011-2015. Since 2015 he has been an Associate Professor of Biomedical Physiology and Kinesiology at Simon Fraser University.
Kevin Betts
Founder & CTO
CTO and co-founder: Mr. Betts received his M.A.Scc. in Engineering Physics at UBC in 1985. With over four decades of diverse experience, he spent his career developing unique, leading-edge technologies and designs. His diverse experience includes signal processing, ASIC design, AI and compression algorithms and control and ultra-low noise electronics designs. He was the architect who implemented the world’s first whole-head MEG-EEG system using DC SQUID-based technologies. Also designed an OPM sensor-based MEG system. Earlier in his career as a principal engineer, Mr. Betts designed a wavelet-based compression algorithm that exceeded H2.64 compression rates and was implemented in ASIC and SIMD architectures. He also designed multiple hi-speed (up to 6GHz) mixed signal ASIC SERDES in processing nodes down to 28nm. In the last ten years, he has worked on AI and SLAM algorithms for image processing. He has over a dozen peer-reviewed publications and multiple patents.
Dr. Tim Roberts
Founder & Inventor
Dr. Timothy Roberts – co-founder, inventor and Principal Investigator of Proteus HAD. Dr. Roberts is the holder of the Oberkircher Family Chair in Pediatric Radiology and Vice-chair of Research in the Dept. of Radiology at the Children’s Hospital of Philadelphia and a tenured Professor of Radiology in the Perelman School of Medicine at the University of Pennsylvania as well as Adjunct Professor of Linguistics in the School of Arts and Sciences at U. Penn. He received his Ph.D. in MRI from Cambridge University in 1992. He has spent his career developing multimodal imaging and electrophysiological techniques for application to neurologic and psychiatric disorders, with a special focus on pediatric developmental disorders such as Autism Spectrum Disorder and related genetic conditions, with a keen focus on auditory and language systems. He has published over 300 peer-reviewed manuscripts in functional and physiological. He serves as an Associate Editor for Frontiers in Integrative Neuroscience. He has been recognized as a Distinguished Investigator of the Academy of Radiology Research (2016) and elected, in the inaugural class, as a Fellow of the American Society of Functional Neuroradiology (ASFNR) in 2019. He is a past president of the International Society for Clinical Magnetoencephalography (ISACM) and the ASFNR. He has served on various committees of the International Society for Magnetic Resonance in Medicine and the American Society of Neuroradiology (ASNR).
Dr. David Embick
Founder & Inventor
Dr. David Embick – co-founder and inventor: Dr. Embick is Professor and Chair in the Department of Linguistics at the University of Pennsylvania. He received his Ph.D. in Linguistics from the University of Pennsylvania and subsequently did postdoctoral work in Neurolinguistics at MIT and the University of Tokyo before joining Penn Linguistics as a faculty member in 2000. His published work covers different areas of language and cognition, including several areas within theoretical linguistics; neurolinguistics; psycholinguistics; and clinical language impairment in children (Autism Spectrum Disorder in particular). He published the monograph Localism versus Globalism in Morphology and Phonology (MIT Press), and in The Morpheme (Mouton de Gruyter); a third book is to be published later this year. His work has also been reported in a large number of peer-reviewed articles in specialist journals, including Linguistic Inquiry, The Journal of Memory and Language, Cognition, Language Cognition and Neuroscience, The Journal of Autism and Developmental Disorders, and The Proceedings of the National Academy of Sciences. His work on language in clinical populations has produced an issued patent that looks directly at using fine-tuned psycho- and neurolinguistic methods for diagnosis and guiding therapeutic interventions in ASD.